about
Cardiorenal end points in a trial of aliskiren for type 2 diabetesSymmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuriaMulticentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.Diagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesPrevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.Implementation of proteomic biomarkers: making it work.Urinary proteomics for early diagnosis in diabetic nephropathy.Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes.Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentreMultifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study.Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.Effect of large weight reductions on measured and estimated kidney function.Direct renin inhibition in chronic kidney disease.Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease.Sequential RAAS blockade: is it worth the risk?Microalbuminuria: a parameter that has changed diabetes care.Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients.Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.Postural stability after inguinal herniorrhaphy under local infiltration anaesthesia.A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.[Clinical use of estimated glomerular filtration rate for evaluation of kidney function].Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
P50
Q28278569-00B8B348-69D0-4290-837E-19C647664255Q33893655-FEC20C38-7E85-4C65-8DF3-C822BC26963FQ33985444-F59A7E0E-0C2C-4FBB-BFA4-F8509AB580CDQ34237280-F8475457-3918-4594-9A0C-FE88D5508B4BQ34926825-ECFD0448-2BB0-4930-9FE9-A942DDCD808DQ34940648-FCA83EEB-B2A3-435E-A703-E85E2342D1ADQ35043750-78B0746F-82B0-46B7-92C6-363D34F93019Q35144449-9A531FF3-5866-460B-8AE2-580E09D87D55Q35179914-CEC05762-58D2-4C69-8B83-0BCAF53DE10FQ35903097-95B03CC7-78D7-4022-8AB3-2A4D3524E052Q36094286-A38097CC-7382-4D4E-992E-0CBD358B1E32Q36297774-124EC228-BAD8-4706-A0DA-6C647A509A01Q36410737-F1CA2913-119D-4D58-9E19-FC42E545AC11Q36629673-E16FEE44-4392-4314-B9BC-74213FFF952DQ36670632-3A9401F4-035F-4830-9F64-2BA11289D8A4Q36818924-DC1B817C-19C7-4CC5-8E56-EE1AE78FCADBQ37067140-971F2B17-7E7E-45D8-A76F-954C728EFBA3Q37153153-916B3E56-75F8-4243-A8F7-108296F9936AQ37364926-8CE8AA3D-037D-4EE0-9EFC-B5CA06485113Q37628031-B766CB58-8647-4993-A6F0-A2B41E286DDCQ38070781-049BAF86-3C51-4454-8106-620A934C4074Q38193086-36ACC2A9-AFA7-459F-897C-57604D7759C8Q38193929-C587482E-A97E-4AB2-B665-9294FD7DE761Q38281767-CB65DD37-DF2B-4348-BB29-FE2A9E362D26Q38412125-22D28578-9285-448F-ABC2-8A27107472A4Q38638362-AEDA9027-9A68-4A83-A68C-F3359409C3E2Q38699857-6F5D6EC6-7FB8-4589-BFDC-1832AEC25C0EQ38737540-8D9F8C9E-5F78-4316-9166-B9FE9B0B9225Q40567052-18A03E79-08BD-4D99-8059-0B718A1ACD9DQ40628662-ABA7ABD6-32C4-4B28-AA42-D792A23DC506Q40972293-A4618707-AEBE-4788-86E3-FECE45F59163Q41173770-6F66F965-D18B-4020-B08A-CEA552D58E09Q43060810-2601229A-697D-4DA5-B2D2-5D96B7140B26Q43686652-7CF33E48-C027-491B-82CE-A944228E8F95Q44319128-5F68E8A9-9812-4773-B91F-0C0E539A2C9DQ44455773-34D42532-7116-4947-B1C7-E32AF40057A6Q45294251-DE208A70-B847-434C-90CA-C9330143ACAAQ45895002-7D79673A-0A44-4335-A2D2-42D696B17353Q46085830-1CD498A0-ED22-45B6-9312-5A108D77F5CAQ46272004-F114883F-BC71-4554-AB36-9C6571961BE6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Frederik Persson
@ast
Frederik Persson
@en
Frederik Persson
@es
Frederik Persson
@nl
Frederik Persson
@sl
type
label
Frederik Persson
@ast
Frederik Persson
@en
Frederik Persson
@es
Frederik Persson
@nl
Frederik Persson
@sl
prefLabel
Frederik Persson
@ast
Frederik Persson
@en
Frederik Persson
@es
Frederik Persson
@nl
Frederik Persson
@sl
P214
P1053
E-6973-2015
P106
P1153
15521088200
P21
P214
P31
P3829
P496
0000-0001-6242-6638
P734
P735
P7859
viaf-307267161